Ads
related to: second line treatment for hcc in liver function- Unresectable HCC Therapy
Combination Treatment For
Unresectable HCC. Visit Site.
- View The Dosing Regimen
See The Dosing Schedule For A
Unresectable HCC Treatment
- Clinical Study Data
View Data For An Unresectable
Hepatocellular Carcinoma Treatment.
- Official Oncologist Site
Visit Official HCP Site To Learn
About An Immunotherapy Option.
- Safety Info From A Study
See Adverse Reaction Data For A
First-Line Unresectable HCC Therapy
- Connect With A Rep
Have Questions? Find Your Local
Representative To Get Answers.
- Unresectable HCC Therapy
Search results
Results From The WOW.Com Content Network
In 2007, sorafenib, an oral multikinase inhibitor, was the first systemic agent approved for first-line treatment of advanced HCC. [76] Trials have found modest improvement in overall survival: 10.7 months vs 7.9 months and 6.5 months vs 4.2 months. [77] [76] The most common side effects of Sorafenib include a hand-foot skin reaction and ...
Under current OPTN/ONUS guidelines, patients with cirrhosis and HCC who meet these criteria may be considered for transplantation. [2] Depending on the treatment algorithm, additional factors such as advanced liver disease (as classified by Child-Pugh score ) or evidence of portal hypertension may also affect suitability for transplantation.
When imaging the liver with ultrasound, large lesions are likely to be HCC (e.g., a mass greater than 2 cm has more than 95% chance of being HCC).Given the blood flow to the liver, HCC would be most visible when the contrast flows through the arteries of the liver (also called the arterial phase) rather than when the contrast flows through the ...
Cabozantinib is being researched [26] for efficacy as a treatment for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), cervical cancer, colorectal cancer (CRC), urothelial cancer, prostate cancer, gastric and gastroesophageal cancer, bladder cancer, melanoma, merkel cell carcinoma, brain cancers (including glioblastoma multiforme and ...
Micrograph showing a PD-L1 positive non-small cell lung carcinoma. PD-L1 immunostain. As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin-based chemotherapy and have high levels ...
Transarterial bland embolization (TAE, also known as HAE) is a catheter-based tumor treatment of the liver.In this procedure, embolizing agents (e.g., polyvinyl alcohol, gelfoam, acrylic copolymer gelatin particles, embospheres) can be delivered through the tumor's feeding artery in order to completely occlude the tumor's blood supply.
Ads
related to: second line treatment for hcc in liver function